| Ytd | -13.70% | |
| 1y | -51.72% |
| Open | 3.16 | Prev Close | 3.10 | Low | 1.26 | High | 3.23 | Mkt Cap | 8.43M |
| Vol | 0.00 | Avg Vol | 1.11M | EPS | -6.82 | P/E | -0.18 | Forward P/E | -0.10 |
| Beta | 1.48 | Short Ratio | 0.03 | Inst. Own | 0.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.58 | 200-d Avg | 3.04 | 1yr Est | 160.00 |
SONN News
Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Und
PRINCETON, N. J. , Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. , (NASDAQ
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: S
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is co
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SO
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
Sonnet BioTherapeutics Inc. SONN stock surged Monday amid high trading volume following news of a tr
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its t
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonne
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezoliz
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SO
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SO
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-app
Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resis
On-demand video webcast now available here
On Thursday, 369 companies hit new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
On Tuesday, 120 companies set new 52-week lows.
On Friday morning, 446 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.